| 2025年中报 | 2024年年报 | 2023年年报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 产品销售(元) | 146,247,537.37 | 287,365,318.75 | 204,534,114.14 |
| 医药研发与定制化生产(元) | 8,548,543.56 | 19,851,243.85 | 51,668,330.59 |
| 营业成本(元) | |||
| 产品销售(元) | 29,861,386.76 | 72,125,684.28 | 59,134,348.85 |
| 医药研发与定制化生产(元) | 5,775,178.50 | 14,427,444.04 | 40,049,940.76 |
| 毛利(元) | |||
| 产品销售(元) | 116,386,150.61 | 215,239,634.47 | 145,399,765.29 |
| 医药研发与定制化生产(元) | 2,773,365.06 | 5,423,799.81 | 11,618,389.83 |
| 毛利率(%) | |||
| 产品销售(%) | 79.58 | 74.90 | 71.09 |
| 医药研发与定制化生产(%) | 32.44 | 27.32 | 22.49 |
| 收入构成(%) | |||
| 产品销售(%) | 94.48 | 93.54 | 79.83 |
| 医药研发与定制化生产(%) | 5.52 | 6.46 | 20.17 |
| 毛利构成(%) | |||
| 产品销售(%) | 97.67 | 97.54 | 92.60 |
| 医药研发与定制化生产(%) | 2.33 | 2.46 | 7.40 |